{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Study drug associated adverse events during therapy","groups":[{"description":"CYCLE 1: Patients receive salsalate PO BID until completion of cycle 1. 24-48 hours later or concurrent with salsalate, patients begin to receive decitabine IV for 10 days or azacitidine IV for 7 days. Starting 24 hour after salsalate, patients also receive venetoclax PO continuously until completion of cycle 1.\n\nCYCLE 2: Patients receive decitabine IV for 5 days or azacitidine IV for 7 days, salsalate PO BID, and venetoclax PO continuously.\n\nCycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given IV\n\nDecitabine: Given IV\n\nSalsalate: Given PO\n\nVenetoclax: Given PO","id":"OG000","title":"Treatment (Salsalate, Decitabine, Azacitidine, Venetoclax)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"During the first 2 cycles, 56 days total","title":"Number of Participants Experiencing Adverse Events Incidence With of Salicylate + Venetoclax + Decitabine","type":"PRIMARY","unitOfMeasure":"Participants"}